ARS Pharmaceuticals Inc (SPRY)
ARS Pharmaceuticals, Inc. is a San Diego, California-based biopharmaceutical company founded in 2015 and listed on the NASDAQ under the ticker SPRY. The company focuses on developing and commercializing treatments for severe allergic reactions in the United States and internationally. Its lead product candidate is neffy, a needle-free intranasal epinephrine delivery system being developed for the emergency treatment of Type I allergic reactions, including anaphylaxis. As a common equity security, SPRY represents ownership in the company rather than a fund, depositary receipt, or other specialized instrument.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-SPRY
|
$5.58
|
24.7% Upside
|
Undervalued
|
$22.50
|
402.2% Upside
|
Bargain
|
Weak
|
0.0%
|
November 17, 2026
|
34.6x
|
3.7x
|
445.5 M
|
460.4 M
|
28.4%
|
48.3%
|
-3.2
|
91.3%
|
